Navigation Links
Sopherion Therapeutics Announces Completion of Enrollment in Phase III Study of Myocet in Metastatic Breast Cancer
Date:3/18/2009

PRINCETON, N.J., March 18 /PRNewswire/ -- Sopherion Therapeutics, LLC, a biopharmaceutical company focused on the development and commercialization of anti-cancer therapies, announced that it completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin (Myocet(TM)) in metastatic HER-2-overexpressing breast cancer. This is a pivotal Phase III trial of Sopherion's lead product in combination with the current standard of care, paclitaxel (Taxol) and trastuzumab (Herceptin(R)), vs. paclitaxel and trastuzumab alone. Progression-free survival (PFS) is the primary efficacy endpoint, with careful monitoring for cardiac safety.

Dr. Jose Baselga, Chairman & Professor of Medicine, Vall d'Hebron Institute of Oncology (V.H.I.O.), Vall d'Hebron University Hospital in Barcelona, Spain, and principal investigator for the trial, said, "I am pleased to see that the recruitment phase of the Phase III trial has now been completed. This registration trial is based on our recently published, Roche-supported study conducted by the Spanish Breast Cancer Cooperative Group (SOLTI). Results showed that Myocet, in combination with trastuzumab and paclitaxel treatment, yielded an unusually high clinical response rate and time to progression in patients with HER-2 overexpressing breast cancer; the 3 drug combination was well tolerated with no cases of treatment-related symptomatic congestive heart failure. "

Phase III Study Design

The study is a global, randomized, multicenter pivotal Phase III study in 363 patients who have metastatic HER-2-overexpressing breast cancer. Eligibility criteria included no prior chemotherapy for metastatic disease, nor any trastuzumab, anthracyclines or taxanes within the previous 12 months. Eligible patients were randomized to receive either Myocet, paclitaxel and trastuzumab, or paclitaxel and trastuzumab alone in a 1:1 randomiza
'/>"/>

SOURCE Sopherion Therapeutics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sopherion Therapeutics Secures $55 Million in Series C Funding
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. FDA Accepts IND for Arno Therapeutics Pan-DAC / Akt Inhibitor, AR-42
4. Sirion Therapeutics Supplemental New Drug Application for Durezol(TM) to Treat Uveitis is Accepted for Review by the FDA
5. United Therapeutics Announces Probable Delay in Approval Timeline for Inhaled Treprostinil (Tyvaso)
6. Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results
7. Cell Therapeutics, Inc. (CTI) to Present at 8th Annual WBBA Invest Northwest Conference
8. Michael J. Fox Foundation Commits Up To $5 Million for Pre-Clinical Drug Development Under Industry-Exclusive Therapeutics Development Initiative
9. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
10. Cell Therapeutics, Inc. (CTI) to Report Fourth Quarter and Year-End Financial Results on March 16
11. Amicus Therapeutics to Present at the Cowen and Company 29th Annual Healthcare Conference on March 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... ... Apex Therapeutics announced today that company CEO, David Broecker provided a company update ... took place on Tuesday, June 16 and provided an update on the achievement of ... of pancreatic cancer. A copy of the company overview can be found on ...
(Date:6/30/2015)... ... 2015 , ... Students and faculty from Beijing City University ... “Integrative Biotechnology,” an applied biotechnology course team-taught by faculty members from both institutions. ... from both universities and is taught on both continents. , “Our alliance with ...
(Date:6/30/2015)... June 30, 2015  Juniper Pharmaceuticals, Inc. (Nasdaq: ... developing therapeutics that address unmet medical needs in ... Elston will present at the Cantor Fitzgerald ... 8, 2015Time: , 4:45 PM EDTLocation: , Le ... archive): , www.juniperpharma.com, under  ,Investor, or  ...
(Date:6/30/2015)... Falls Church, VA (PRWEB) , ... June 30, ... ... technology, and strategy services to the federal government, announced in a paper published ... Noblis scientists uncovered a potential problem with the diagnostic techniques currently used to ...
Breaking Biology Technology:Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4
... CRANBURY, N.J., Sept. 24 Palatin Technologies, Inc. (NYSE ... of its workforce and operations to reflect a strategic ... objectives. As a result, Palatin will focus resources and ... female sexual dysfunction and PL-3994 for acute severe asthma. ...
... 24, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
... Cylene Pharmaceuticals, Inc. announced today the initiation ... first-in-class, oral CK2 inhibitor CX-4945 in patients with ... of a $12 million financing with participation from ... Ltd., Novartis BioVenture Fund, BioVentures Investors, Lilly Ventures, ...
Cached Biology Technology:Palatin Announces Strategic Realignment of Operations 2Palatin Announces Strategic Realignment of Operations 3Palatin Announces Strategic Realignment of Operations 4Palatin Announces Strategic Realignment of Operations 5Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 2Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 3Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 4Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 5Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 6Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone 7Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing 2Cylene Initiates Phase I Trial in Multiple Myeloma With CX-4945 Inhibitor of CK2 and Closes Accompanying Financing 3
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, a ... with specialties in single use solutions, headquartered in ... Inc. (a California corporation with locations ... San Jose, Costa Rica ). This ... Rica with ATL Technology,s existing facility in ...
(Date:6/25/2015)... CITY , June 25, 2015  Imagine a ... steps toward a healthier, happier life. That,s exactly what ... designed to do. The cutting-edge, portable health program provides ... real-life solutions to help improve your lifestyle and nutrition. ... awards dinner and gala Wednesday night, USANA,s THA was ...
(Date:6/24/2015)... YORK , June 24, 2015 The ... rate. The major drivers for the market include growth ... number of new drug launches. Over the years, the ... increased. Between 2001 and 2010, the FDA approved 225 ... according to WIPO, Europe accounted ...
Breaking Biology News(10 mins):ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... by wood-eating gribble that destroyed their ships, and these ... docks in coastal communities. , But new research ... the Universities of York and Portsmouth is uncovering how ... , By examining genes that are expressed in the ...
... ITHACA, N.Y. - Another weapon in the arsenal ... cancer cells while leaving healthy cells alone. Led ... Food Science, the researchers synthesized nanoparticles shaped something ... two pieces of iron oxide. They then attached antibodies, ...
... BINGHAMTON, NY -- In his recent book, "Strategic Bargaining ... Yang suggests ways governments might realistically work together to ... for curbing the use of fossil fuels whether ... global warming is factually true and I,m not ...
Cached Biology News:Seafarers' scourge provides hope for biofuel future 2Like little golden assassins, 'smart' nanoparticles identify, target and kill cancer cells 2Cool model for a hot planet 2Cool model for a hot planet 3